| Symbol | AIXC |
|---|---|
| Name | QUALIGEN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2042 CORTE DEL NOGAL,SUITE B, CARLSBAD, California, 92011, United States |
| Telephone | +1 760 918-9165 |
| Fax | — |
| — | |
| Website | https://www.qlgntx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. Additional info from NASDAQ: |
New Form S-8 - AIxCrypto Holdings, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001493152-26-017872 <b>Size:</b> 404 KB
Read more(99% Neutral) QUALIGEN THERAPEUTICS, INC. (AIXC) Announces Business Combination
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: RWA Exploration, Ecosystem Development, and External Engagement
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: AI Agent Development and Internal Testing Progress
Read moreAIxCrypto Highlights Full Year 2025 Transformation and Next Phase of Growth
Read moreNew Form 10-K - AIxCrypto Holdings, Inc. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001493152-26-013434 <b>Size:</b> 11 MB
Read moreAIXCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Real Estate Industry Engagement, Long-Term Infrastructure Direction, and Industry Signals From the Evolving AI Stack
Read moreAIxCrypto Acknowledges Conclusion of SEC Investigation with no Enforcement Action Involving majority controlling stockholder, Faraday Future and Reaffirms Strategic Focus
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Exploration of Infrastructure for the Emerging AI Agent Economy
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Agent Ecosystem Application Progress and Infrastructure Development
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06086522 | Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced … | Phase1 | Solid Tumor | Recruiting | 2023-11-01 | 2026-12-01 | ClinicalTrials.gov |